Cargando…
Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
INTRODUCTION: Due to the difficulty of early diagnosis, nearly 70% of ovarian cancer patients are first diagnosed at an advanced stage. Thus, improving current treatment strategies is of great significance for ovarian cancer patients. Fast-developing poly (ADP-ribose) polymerases inhibitors (PARPis)...
Autores principales: | Tang, Bin, Wu, Min, Zhang, Lin, Jian, Shuyi, Lv, Shiyi, Lin, Tongyuan, Zhu, Shuangshuang, Liu, Layang, Wang, Yixue, Yi, Zhengfang, Jiang, Feiyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151711/ https://www.ncbi.nlm.nih.gov/pubmed/37143950 http://dx.doi.org/10.3389/fonc.2023.1154073 |
Ejemplares similares
-
Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021) -
Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020) -
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020) -
Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021) -
Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)